Zenosense, Inc. (ZENO) Extends Agreement with Sgenia Group to Include Sensory Devices

Zenosense is a healthcare technology company focused on developing and marketing a device for use in hospitals and various healthcare environments to detect the Methicillin-resistant Staphylococcus aureus (MRSA) “Super-Bug,” has announced that the company has extended its agreement with the Sgenia Group (“Sgenia”) to include cancer sensory devices. Under the terms of the extension, Zenosense has the optional right to fund the development of prospective cancer sensory devices that may be based on the Sgenia technology. Subject to providing funding, the company will have the right to make, market, and sell the resulting devices should they be developed.

ZENO believes the sensory technology and algorithmic processing in development for MRSA detection could be applied to certain cancer sensory devices if successful. Cancers, such as lung and colon, produce volatile organic compounds (“VOCs”) in an individual’s breath in a similar way to patients infected with MRSA. Should the cancer specific pattern of VOCs be identified, the company believes that a relatively straightforward modification of a successful MRSA detection technology may help it to produce a similar device for the detection of certain cancers.

Zenosense’s work causes it to believe there could be significant demand for a low cost, rapid detection device for these types of cancer. A device of this nature could allow for much wider screening and the ability to detect, for example, lung cancer at a much earlier stage and on a mass scale. Currently lung cancer is typically caught at a late stage when fewer than 25% of cases can be cured, however, in Stage I there is a 70% cure rate.

Zenosense is a detection device development company based in Valencia, Spain whose work involves developing, marketing, and selling an effective MRSA detector, by way of licensed-in technology, for sale to healthcare providers for use in clinical settings. The company believes there is enormous dormant demand for a cost-effective MRSA detector, driven by the costs associated with the late detection of MRSA, and that it has identified a valuable new market segment for a wearable detection device. The development and exclusive license agreement also includes cancer sensory devices.

For more information on the company, visit www.zenosense.net

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net